STAGE IVA OROPHARYNGEAL SQUAMOUS CELL CARCINOMA AJCC V7
Clinical trials for STAGE IVA OROPHARYNGEAL SQUAMOUS CELL CARCINOMA AJCC V7 explained in plain language.
Never miss a new study
Get alerted when new STAGE IVA OROPHARYNGEAL SQUAMOUS CELL CARCINOMA AJCC V7 trials appear
Sign up with your email to follow new studies for STAGE IVA OROPHARYNGEAL SQUAMOUS CELL CARCINOMA AJCC V7, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to extend life in advanced head and neck cancer
Disease control OngoingThis phase 3 trial tested whether adding bevacizumab to standard chemotherapy helps people with head and neck cancer that has returned or spread. About 403 adults took part. The main goal was to see if the combination improved overall survival compared to chemotherapy alone.
Matched conditions: STAGE IVA OROPHARYNGEAL SQUAMOUS CELL CARCINOMA AJCC V7
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Proton beam vs. X-Ray: which radiation is safer for throat cancer?
Disease control OngoingThis phase 3 trial compares two types of radiation therapy for advanced throat cancer: standard photon radiation (IMRT) and newer proton beam therapy (IMPT). The goal is to see if proton therapy causes fewer severe side effects while still controlling the cancer. About 440 patien…
Matched conditions: STAGE IVA OROPHARYNGEAL SQUAMOUS CELL CARCINOMA AJCC V7
Phase: PHASE3 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New drug duo shows promise against tough head and neck cancers
Disease control OngoingThis study tests two drugs, pembrolizumab and cabozantinib, in 36 people with head and neck cancer that has returned or spread and cannot be surgically removed. The goal is to see if the combination shrinks tumors and delays cancer growth. Participants receive both drugs intraven…
Matched conditions: STAGE IVA OROPHARYNGEAL SQUAMOUS CELL CARCINOMA AJCC V7
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC